BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Reports Second Quarter 2026 Financials

Jaguar Health (JAGX)Jaguar HealthEarnings

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of

Related news

JAGXJaguar Health2026-05-20 20:40 EST

Jaguar Health Reports First Quarter 2026 Financials

SCYXSCYNEXIS2026-08-10 20:30 EST

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

JAGXJaguar Health2026-08-18 13:00 EST

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

HROWHarrow, Inc.2026-08-10 20:05 EST

Harrow Announces Second Quarter 2026 Financial Results

HROWHarrow, Inc.2026-07-27 11:00 EST

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

VIRXViracta Therapeutics2024-11-13 12:00 EST

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

IBRXImmunityBio2026-08-04 11:30 EST

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

IBRXImmunityBio2026-04-09 11:30 EST

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

ALZNAlzamend Neuro2025-07-23 12:00 EST

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-08-19 20:00 EST

Jaguar Health Reports Second Quarter 2026 Financials

JAGXJaguar Health2026-08-18 13:00 EST

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

JAGXJaguar Health2026-08-05 13:00 EST

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

JAGXJaguar Health2026-07-28 13:00 EST

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

JAGXJaguar Health2026-07-22 13:00 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Stock data

Close
0.87 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California